查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2017518

骨关节炎镇痛药市场：2026年至2032年全球市场预测（按产品类型、给药途径、患者年龄层、疾病严重程度、最终用户和分销管道划分）

Osteoarthritis Pain Drug Market by Product Type, Route Of Administration, Patient Age Group, Disease Severity, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年，骨关节炎镇痛药市值为94.5亿美元，预计2026年将成长至103.1亿美元，复合年增长率为9.62%，到2032年将达到179.9亿美元。

主要市场统计数据
基准年 2025 94.5亿美元
预计年份：2026年 103.1亿美元
预测年份 2032 179.9亿美元
复合年增长率 (%) 9.62%

对不断发展的骨关节炎镇痛市场进行策略概述，提出临床挑战、患者多样性以及相关人员的实用创新途径。

由于患者需求各异、慢性疼痛病程复杂，以及不同年龄层和疾病严重程度的患者功能受损程度存在差异，骨关节炎仍是一个复杂的临床挑战。临床医生和保险公司越来越倾向于寻求能够在快速缓解症状、长期用药安全性以及对运动功能和生活品质产生显着改善之间取得平衡的治疗方法。近期的临床创新主要集中于改善现有药物类别，并探索新的机制，以解决持续疼痛管理和疾病进展方面尚未解决的难题。

科学、临床和商业性的变革正在重塑骨关节炎疼痛管理的整体情况，重新定义治疗方案、剂量形式和对证据的期望。

在科学进步、支付方期望变化以及技术驱动的医疗模式的推动下，骨关节炎药物市场正经历着一场变革。生物製药和标靶小分子化合物正在重新定义治疗的可能性，而药物科学也持续提供能够提高耐受性和依从性的治疗方案。同时，数位健康平台和远端监测的出现使得对疼痛进展和功能改善的评估更加精准，从而支持了基于疗效的医保合约和个人化治疗流程。

分析研究到 2025 年的定价政策趋势如何重塑骨关节炎药物的供应链、製造地和采购重点。

到2025年，累积贸易措施和关税政策调整将对骨关节炎治疗药物的供应链、生产经济和筹资策略产生多方面的影响。关键中间体和成品进口关税的提高，加剧了依赖跨国分销活性原料药（API）和辅料的企业的投入成本波动。因此，製造商和合约研发生产机构（CDMO）正在加快供应商多元化，扩大本地灌装和包装能力，并重新审视长期采购合同，以降低关税带来的成本增加风险。

实用的细分见解揭示了产品类型、给药途径、分销管道趋势和患者人口统计特征如何系统地决定临床定位和商业策略。

基于细分的骨关节炎治疗生态系统分析揭示了清晰的临床和商业性特征，这些特征指南跨治疗领域和给药途径的产品策略。就产品类型而言，皮质类固醇仍主要用于控制急性发作，而Cyclooxygenase-2抑制剂和非类固醇消炎剂在全身症状控制中继续发挥基础性作用。同时，缓释对症药物在长期症状调节方面占据独特的地位，而黏弹性补充剂则在关节内给药领域占据着特定的细分市场，为寻求局部动态支持的患者提供服务。给药途径影响临床定位和应用趋势；注射剂分为关节内给药（用于标靶关节治疗的首选）和肌肉注射（用于特定治疗路径）。口服剂分为胶囊、液体和片剂，以满足患者的用药依从性和剂量需求，而外用疗法则以乳膏、凝胶和贴剂的形式提供，以满足优先考虑安全性或合併其他疾病的患者群体的需求。

区域战略资讯解释了美洲、欧洲、中东和非洲以及亚太地区的趋势如何决定市场准入、采用和製造优先事项。

区域趋势正以显着不同的方式影响临床应用、监管方法和供应链设计。在美洲，医疗保健系统和私人保险公司专注于成本效益和可持续的功能性获益的证据，这加速了人们对能够显着改善患者活动能力并减少急诊资源使用的治疗方法的兴趣。北美强大的生产能力和成熟的专科医疗保健基础设施支持先进注射剂和联合疗法方案的快速推广，但采购流程日益严格的审查也提高了人们对透明供应保障的期望。

雇主层面的洞察，展示如何利用产品创新、伙伴关係和製造韧性来确保商业性和临床差异化。

骨关节炎疼痛管理领域的主要企业正采取多元化但又互补的策略，以保持竞争力并实现临床差异化。许多公司正在投资研发新一代製剂，以提高药物对关节的标靶暴露量，同时降低全身暴露量，进而改善老年患者和合併其他疾病患者的耐受性。生物技术开发商、专科药房和分销合作伙伴之间的策略合作正被充分利用，以加速产品进入市场，提高患者用药依从性，并建立长期的患者支援服务，收集真实世界的疗效数据。

从支付方的观点，为製造商和相关人员提供切实可行的建议，以加强骨关节炎治疗的供应韧性、临床意义和价值证明。

产业领导者应采取多管齐下的策略，以保持发展势头并应对短期挑战，同时建立长期竞争优势。首先，他们应优先考虑供应商多元化，并投资于本地灌装、包装和无菌生产能力，以降低跨境贸易波动风险，并满足医院对供应韧性的采购要求。其次，产品开发应与实际临床需求相契合，重点在于能够提高老年人用药安全性、便于门诊给药以及减轻居家看护者负担的剂型。第三，他们应加快累积将药物疗效、功能性结果和医疗资源可用性联繫起来的真实世界证据，从而支持与支付方的对话以及基于结果的合约。

本文清楚地阐述了一种混合方法研究方法，整合了主要临床发现、次要资讯和基于情境的分析，从而确保了严谨而实用的见解。

本研究采用混合方法，结合与关键相关人员的对话、有针对性的二手资讯收集和定量分析，以得出可靠且可操作的结论。主要研究包括对执业风湿症医师、骨科医生、支付方、医院采购经理和製药公司高管进行结构化访谈，以了解治疗偏好、处方集趋势和采购因素。二手资讯收集自同行评审的临床文献、监管出版刊物、公开的临床试验註册资讯、专利申请和检验的供应链资料库，从而对治疗趋势、研发管线活动和製造地分布进行多方面分析。

对相关人员在不断发展的骨关节炎治疗领域取得成功必须整合的临床、商业性和营运要求进行权威的综合分析。

总之，骨关节炎镇痛药市场正受到临床创新、分销管道演变和供应链需求的重塑，这些因素共同定义了新的商业性和临床成功标准。有效的策略取决于透过标靶製剂和给药机制提供差异化的临床价值，同时展现对保险公司和临床医生至关重要的实际功能性获益。以区域生产安排和透明采购惯例为基础的供应韧性是商业性信誉的关键要素。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：骨关节炎止痛药市场：依产品类型划分

  • 皮质类固醇
  • Cyclooxygenase2抑制剂
  • 非类固醇消炎剂
  • 症状治疗及缓释药物
  • 黏弹性补充剂

第九章：骨关节炎镇痛药市场：依给药途径划分

  • 注射药物
    • 关节内
    • 肌肉内部
  • 口服
    • 胶囊
    • 液体
    • 药片
  • 外用
    • 奶油
    • 凝胶
    • 修补

第十章：依患者年龄层分類的骨关节炎镇痛药市场

  • 18岁以下的青少年
  • 18-64岁的成年人
  • 65岁及以上的老年人

第十一章 骨关节炎镇痛药市场：依疾病严重程度划分

  • 温和的
  • 缓和
  • 严重

第十二章 骨关节炎镇痛药市场：依最终用户划分

  • 诊所
  • 家庭医疗保健
  • 医院

第十三章：骨关节炎镇痛药市场：依通路划分

  • 离线
  • 在线的

第十四章：骨关节炎止痛药市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：骨关节炎止痛药市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 骨关节炎止痛药市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国骨关节炎止痛药市场

第十八章：中国骨关节炎止痛药市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Bayer AG
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-0376B2CAAFEB

The Osteoarthritis Pain Drug Market was valued at USD 9.45 billion in 2025 and is projected to grow to USD 10.31 billion in 2026, with a CAGR of 9.62%, reaching USD 17.99 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.45 billion
Estimated Year [2026] USD 10.31 billion
Forecast Year [2032] USD 17.99 billion
CAGR (%) 9.62%

A strategic introduction to the evolving osteoarthritis pain drug environment that frames clinical imperatives, patient diversity, and practical innovation pathways for stakeholders

Osteoarthritis remains a complex clinical challenge driven by heterogeneous patient needs, chronic pain trajectories, and variable functional impacts across age groups and disease severity. Clinicians and payers increasingly seek therapies that balance rapid symptom relief, safety for long-term use, and demonstrable effects on mobility and quality of life. Recent clinical innovation has focused on refining existing pharmacologic classes and exploring novel mechanisms to address persistent gaps in durable pain control and disease progression.

Against this backdrop, manufacturers are adapting development priorities to emphasize differentiated delivery formats, improved safety profiles for older adults, and solutions compatible with ambulatory and home-based care models. Concurrently, health systems and specialty clinics are demanding evidence that links product performance to real-world functional outcomes. This introduction sets the stage for a detailed examination of therapeutic classes, route-of-administration trends, distribution dynamics, and patient segmentation that together shape the commercial and clinical contours of the osteoarthritis pain drug space.

Transformative scientific, clinical, and commercial shifts reshaping therapeutic choices, delivery formats, and evidence expectations across the osteoarthritis pain landscape

The osteoarthritis drug landscape is undergoing transformative shifts driven by scientific advances, shifting payer expectations, and technology-enabled care models. Biologic approaches and targeted small molecules are redefining therapeutic possibilities, while formulation science continues to deliver options that improve tolerability and adherence. At the same time, the emergence of digital health platforms and remote monitoring is enabling more precise assessment of pain trajectories and functional improvement, which in turn supports outcomes-based contracting and personalized treatment algorithms.

Commercially, manufacturers are responding to these shifts through strategic alliances, specialty partnerships, and differentiated go-to-market strategies that prioritize high-value clinical niches. As regulatory pathways adapt to accommodate real-world evidence and accelerated approvals, the ability to generate robust post-authorization data will determine which candidates achieve sustainable uptake. In addition, ongoing improvements in sterile injectable manufacturing and advanced topical formulations are changing how clinicians select therapies across care settings, from clinics to home-based care, which reinforces the importance of aligning development with practical delivery constraints.

An analytical view of how tariff developments through 2025 have reshaped supply chains, manufacturing footprints, and procurement priorities across osteoarthritis therapeutics

The cumulative trade measures and tariff policy shifts introduced through 2025 have imparted a multifaceted impact on supply chains, manufacturing economics, and procurement strategies for osteoarthritis therapeutics. Increased duties on key intermediates and finished imports have elevated input cost volatility for companies reliant on cross-border API and excipient flows. As a direct consequence, manufacturers and contract development and manufacturing organizations have accelerated supplier diversification, expanded local fill-finish capacity, and reevaluated long-term sourcing agreements to mitigate exposure to tariff-driven cost escalation.

Beyond cost considerations, tariffs have influenced strategic decisions around where to locate high-volume sterile manufacturing versus specialized formulation work. Injectable therapies, which require stringent sterile processes and validated cold-chain logistics, have seen heightened attention to domestic or regionally proximate production to reduce cross-border complexity. Conversely, topical and oral formulations with longer shelf stability have provided more flexibility to absorb tariff-related logistics changes through inventory management and selective sourcing. Payers and hospital procurement teams have responded by intensifying scrutiny of total landed cost and supply resilience, prompting manufacturers to present more transparent supply chain assurances and contingency plans. In sum, tariff dynamics through 2025 have reinforced resilience as a core commercial differentiator, compelling companies to align manufacturing footprint, procurement strategies, and pricing models with evolving trade realities.

Actionable segmentation insights revealing how product types, administration routes, channel dynamics, and patient cohorts systematically determine clinical positioning and commercial strategy

A segmentation-led understanding of the osteoarthritis therapeutic ecosystem reveals distinct clinical and commercial behaviors that inform product strategy across therapeutic classes and delivery routes. In terms of product type, corticosteroids continue to be relied upon for acute flare management while cyclooxygenase 2 inhibitors and nonsteroidal anti-inflammatory drugs remain foundational for systemic symptom control, symptomatic slow-acting drugs serve niche roles in long-term symptom modulation, and viscosupplements occupy a specific intra-articular niche for patients seeking localized biomechanical support. Route of administration shapes clinical positioning and adoption dynamics, with injectable approaches subdividing into intra-articular options favored for targeted joint therapy and intramuscular formats used in specific care pathways, oral administration dividing into capsules, liquid formulations, and tablets to match adherence and dosing needs, and topical therapies offered as creams, gels, and patches that cater to safety-conscious or comorbid populations.

Distribution channel choices reflect purchasing behavior and care setting needs, balancing hospital pharmacy procurement for acute procedural use with retail pharmacy access for chronic management and growing online pharmacy channels that facilitate direct-to-patient fulfillment and adherence programs. End-user segmentation shows distinct expectations across clinics that favor rapid-onset, procedure-compatible options; home healthcare that prioritizes ease-of-use and safety for extended treatment; and hospitals that emphasize efficacy in severe presentations and supply reliability. Age-based considerations-adolescents under 18, adults 18 to 64, and elderly 65 plus-drive formulation and dosing priorities, with the elderly cohort demanding heightened attention to comorbidity interactions and polypharmacy. Finally, disease severity bands of mild, moderate, and severe map directly to therapeutic intensity and delivery format, where milder presentations trend toward topical and oral maintenance therapies and more severe disease necessitates injectable or combined modality strategies. Together, these segmentation dimensions provide a multidimensional framework to prioritize development investments, label positioning, and market access tactics.

Regional strategic intelligence describing how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics determine access, adoption, and manufacturing priorities

Regional dynamics are influencing clinical adoption, regulatory approaches, and supply chain design in markedly different ways across major geographies. In the Americas, health systems and private payers are focusing on cost-effectiveness and evidence of durable functional benefit, which accelerates interest in therapies that can demonstrate measurable improvements in mobility and reduced utilization of acute care resources. North American manufacturing capacity and a mature specialty care infrastructure support rapid adoption of advanced injectables and combination treatment protocols, while procurement scrutiny drives expectations for transparent supply assurances.

In Europe, Middle East & Africa, regulatory heterogeneity and diverse reimbursement mechanisms require targeted market access strategies that align clinical value propositions with local HTA frameworks and payer priorities. The EMEA region also presents significant opportunities to align public health initiatives with aging populations in certain markets, creating demand for safer chronic-use therapies and community-delivered care models. In the Asia-Pacific region, demographic shifts, rapid expansion of specialty clinics, and an agile contract manufacturing sector are fostering faster uptake of novel formulations, although fragmented reimbursement and variable access remain constraints. Across regions, interoperability of real-world data and regional manufacturing investments continue to be decisive factors shaping where companies prioritize launches and scale production lines.

Corporate-level insights showing how product innovation, partnerships, and manufacturing resilience are being deployed to secure commercial and clinical differentiation

Leading companies in the osteoarthritis pain space are pursuing distinct but complementary strategies to preserve competitiveness and capture clinical differentiation. Many are investing in next-generation formulations that reduce systemic exposure while enhancing targeted exposure at the joint, thereby improving tolerability for older adults and patients with comorbidities. Strategic alliances across biotech developers, specialty pharmacies, and distribution partners are being used to accelerate market entry and to build longitudinal patient support services that enhance adherence and gather real-world outcomes data.

On the operational front, firms are strengthening sterile manufacturing capabilities and pursuing geographic diversification to reduce supply chain risk and better align with regional procurement trends. Commercially, there is a growing emphasis on value demonstration through health economic modeling and targeted outcomes studies designed to speak to institutional buyers and payers. Firms that combine clinical differentiation with transparent supply chain credentials and a clear pathway to demonstrate real-world impact are establishing clearer routes to premium positioning within clinical formularies and specialist prescribing environments.

Actionable recommendations for manufacturers and stakeholders to enhance supply resilience, clinical relevance, and payer-aligned value demonstration in osteoarthritis therapeutics

Industry leaders should adopt a multifaceted approach to sustain momentum and address near-term disruptions while building long-term competitive advantage. First, prioritize supplier diversification and invest in regional fill-finish and sterile production capacity to reduce exposure to cross-border trade volatility and to meet hospital procurement expectations for supply resilience. Second, align product development with pragmatic clinical needs by focusing on formulations that improve safety for older adults, enable outpatient administration, and reduce caregiver burden in home healthcare settings. Third, accelerate generation of real-world evidence that links drug performance to functional outcomes and health resource utilization to support payer conversations and outcomes-based contracts.

Further, companies should expand digital engagement and patient support infrastructure to improve adherence and to capture continuous outcomes data that can inform iterative product improvements. Commercial strategies should include targeted channel optimization to balance hospital pharmacy penetration with retail and online pharmacy access, ensuring that distribution meets both acute procedural demand and chronic maintenance needs. Finally, embed scenario planning into procurement and pricing strategies so that tariff changes, supply disruptions, or reimbursement shifts can be accommodated without compromising clinical supply or strategic launch timelines.

Clear explanation of the mixed-methods research approach integrating primary clinical insights, secondary intelligence, and scenario-based analysis to ensure rigorous and actionable findings

This research applied a mixed-methods approach combining primary stakeholder engagement, targeted secondary intelligence, and quantitative synthesis to ensure robust and actionable conclusions. Primary research included structured interviews with practicing rheumatologists, orthopedic surgeons, payers, hospital procurement leads, and senior commercial executives to capture therapeutic preferences, formulary dynamics, and procurement drivers. Secondary inputs were drawn from peer-reviewed clinical literature, regulatory publications, public clinical trial registries, patent filings, and validated supply chain databases to triangulate therapeutic trends, pipeline activity, and manufacturing footprints.

Analytic methods incorporated segmentation mapping, scenario analysis to explore supply disruption and tariff impacts, and cross-validation techniques to reconcile qualitative inputs with observed procurement behaviors. Quality assurance included expert review panels and methodological audits to confirm consistency of thematic findings. Together, these approaches produced a defensible evidence base that links clinical needs, distribution realities, and commercial imperatives to practical recommendations for product development and market access.

Conclusive synthesis of clinical, commercial, and operational imperatives that stakeholders must integrate to succeed in the evolving osteoarthritis therapeutic arena

In conclusion, the osteoarthritis pain drug environment is being reshaped by clinical innovation, distribution evolution, and supply chain imperatives that together define new commercial and clinical thresholds for success. Effective strategies will hinge on delivering differentiated clinical value through targeted formulations and delivery mechanisms, while simultaneously demonstrating real-world functional benefits that matter to payers and clinicians. Supply resilience, evidenced by regional manufacturing and transparent procurement practices, has become a nonnegotiable element of commercial credibility.

Stakeholders who align development portfolios with patient-centric outcomes, invest in evidence generation, and adopt flexible manufacturing and distribution models will be best positioned to navigate the evolving landscape. By integrating these strategic priorities into development and commercialization plans, organizations can better meet the diverse needs of clinicians and patients while maintaining operational agility in a dynamic regulatory and trade environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Osteoarthritis Pain Drug Market, by Product Type

  • 8.1. Corticosteroids
  • 8.2. Cyclooxygenase 2 Inhibitors
  • 8.3. Nonsteroidal Anti-Inflammatory Drugs
  • 8.4. Symptomatic Slow Acting Drugs
  • 8.5. Viscosupplements

9. Osteoarthritis Pain Drug Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intra Articular
    • 9.1.2. Intramuscular
  • 9.2. Oral
    • 9.2.1. Capsules
    • 9.2.2. Liquid
    • 9.2.3. Tablets
  • 9.3. Topical
    • 9.3.1. Cream
    • 9.3.2. Gel
    • 9.3.3. Patch

10. Osteoarthritis Pain Drug Market, by Patient Age Group

  • 10.1. Adolescents Under 18
  • 10.2. Adults 18 64
  • 10.3. Elderly 65+

11. Osteoarthritis Pain Drug Market, by Disease Severity

  • 11.1. Mild
  • 11.2. Moderate
  • 11.3. Severe

12. Osteoarthritis Pain Drug Market, by End User

  • 12.1. Clinics
  • 12.2. Home Healthcare
  • 12.3. Hospitals

13. Osteoarthritis Pain Drug Market, by Distribution Channel

  • 13.1. Offline
  • 13.2. Online

14. Osteoarthritis Pain Drug Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Osteoarthritis Pain Drug Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Osteoarthritis Pain Drug Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Osteoarthritis Pain Drug Market

18. China Osteoarthritis Pain Drug Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Bayer AG
  • 19.7. GlaxoSmithKline plc
  • 19.8. Johnson & Johnson
  • 19.9. Merck & Co., Inc.
  • 19.10. Novartis AG
  • 19.11. Perrigo Company plc
  • 19.12. Pfizer Inc.
  • 19.13. Sandoz International GmbH
  • 19.14. Sanofi S.A.
  • 19.15. Teva Pharmaceutical Industries Ltd.
  • 19.16. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CYCLOOXYGENASE 2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CYCLOOXYGENASE 2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CYCLOOXYGENASE 2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SYMPTOMATIC SLOW ACTING DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SYMPTOMATIC SLOW ACTING DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SYMPTOMATIC SLOW ACTING DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY VISCOSUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY VISCOSUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY VISCOSUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRA ARTICULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRA ARTICULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRA ARTICULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADOLESCENTS UNDER 18, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADOLESCENTS UNDER 18, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADOLESCENTS UNDER 18, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADULTS 18 64, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADULTS 18 64, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADULTS 18 64, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ELDERLY 65+, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ELDERLY 65+, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ELDERLY 65+, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MILD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MILD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MILD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 188. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 189. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 190. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 192. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 218. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 219. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 220. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 221. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 222. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 228. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 229. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 230. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 232. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)